STOCK TITAN

Profound Med Stock Price, News & Analysis

PROF NASDAQ

Company Description

Overview

Profound Med Corp (PROF) is a commercial-stage medical device company renowned for its innovative, incision-free therapeutic systems designed for image-guided ablation of diseased tissue. Leveraging real-time MRI, transurethral therapeutic ultrasound, and closed-loop thermal feedback control, the company has developed a unique solution for the ablation of prostate tissue in prostate cancer patients. This advanced system not only exemplifies the cutting edge of minimally invasive procedures but also integrates seamlessly with the existing imaging infrastructure found in modern healthcare facilities.

Technology and Product Offering

The cornerstone of Profound Med Corp’s product portfolio is the TULSA-PRO system, a state-of-the-art platform that combines several advanced features:

  • Real-Time MRI Guidance: The system harnesses live magnetic resonance imaging to adapt treatment protocols dynamically during the ablation process, ensuring precision and patient-specific customization.
  • Transurethral Therapeutic Ultrasound: Utilizing a robotically driven, sweeping-action approach, the ultrasound component carefully administers thermal energy to target prostate tissue without invasive incisions.
  • Closed-Loop Thermal Feedback Control: This control system allows the procedure to maintain an optimal thermal profile, thereby enhancing accuracy and safety during treatment.

Business Model and Market Position

Profound Med Corp operates within the highly specialized medical device market, focusing on ablation therapies that are both customizable and minimally invasive. The company generates revenue primarily through the sale of one-time use devices and durable equipment that are designed to be used in conjunction with hospitals' and clinics' existing MRI scanners. This integration into existing infrastructure ensures that the system is easily adopted within various clinical settings, supporting ease of transition and cost-efficiency.

Competitive Landscape and Operational Excellence

In a competitive market characterized by rapid technological innovation and stringent clinical requirements, Profound Med Corp distinguishes itself through its emphasis on precision, efficiency, and patient safety. The combination of advanced imaging, ultrasound technology, and thermal regulation is not only technically sophisticated but also strategically positioned to serve a niche yet critical segment of the healthcare market. Investors and industry analysts recognize the company for its steady approach in developing and refining a product that addresses the complexities of prostate ablation with a strong focus on quality and clinical efficacy.

Clinical and Operational Insights

Clinical trials and ongoing studies highlight the system's ability to deliver short treatment times and low morbidity, which are key benefits in improving patient recovery. The robust integration of multiple modalities reflects Profound Med Corp’s commitment to delivering tailored therapeutic options while maintaining operational efficiency in diverse healthcare settings. This carefully engineered approach positions the company as a noteworthy participant in the evolution of non-invasive treatments for prostate cancer and similar conditions.

Industry Expertise and Strategic Integration

Profound Med Corp’s approach is defined by its deep understanding of both the technological and clinical requirements inherent in prostate ablation therapy. By harnessing complex imaging modalities with precision-focused therapeutic techniques, the company bridges the gap between advanced medical engineering and practical clinical application. The strategic utilization of the healthcare system's imaging infrastructure further demonstrates an astute awareness of operational challenges and provides a framework that is both innovative and reliable.

Conclusion

In summary, Profound Med Corp exemplifies a sophisticated blend of medical technology innovation and robust clinical application. Its TULSA-PRO system exemplifies how merging cutting-edge imaging with therapeutic ultrasound can revolutionize treatment protocols, offering a minimally invasive alternative to traditional surgical methods. This comprehensive approach not only drives operational excellence but also reinforces the company’s reputation as a knowledgeable and trusted participant in the medical device industry.

Stock Performance

$4.80
+0.73%
+0.04
Last updated: April 27, 2025 at 15:59
-5.53 %
Performance 1 year
$143.6M
Market Cap
30.1M
Shares outstanding

SEC Filings

No SEC filings available for Profound Med.

Financial Highlights

$10,680,000
Revenue (TTM)
-$27,816,000
Net Income (TTM)
$1.12
Diluted EPS (TTM)
-$23,453,000
Operating Cash Flow
-260.45%
Net Profit Margin
-309.57%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Profound Med (PROF)?

The current stock price of Profound Med (PROF) is $4.765 as of April 25, 2025.

What is the market cap of Profound Med (PROF)?

The market cap of Profound Med (PROF) is approximately 143.6M.

What is the revenue (TTM) of Profound Med (PROF) stock?

The trailing twelve months (TTM) revenue of Profound Med (PROF) is $10,680,000.

What is the net income of Profound Med (PROF)?

The trailing twelve months (TTM) net income of Profound Med (PROF) is -$27,816,000.

What is the earnings per share (EPS) of Profound Med (PROF)?

The diluted earnings per share (EPS) of Profound Med (PROF) is $1.12 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Profound Med (PROF)?

The operating cash flow of Profound Med (PROF) is -$23,453,000.

What is the profit margin of Profound Med (PROF)?

The net profit margin of Profound Med (PROF) is -260.45%.

What is the operating margin of Profound Med (PROF)?

The operating profit margin of Profound Med (PROF) is -309.57%.

What is the gross margin of Profound Med (PROF)?

The gross profit margin of Profound Med (PROF) is 65.89%.

What is the current ratio of Profound Med (PROF)?

The current ratio of Profound Med (PROF) is 10.52, indicating the company's ability to pay short-term obligations.

What is the gross profit of Profound Med (PROF)?

The gross profit of Profound Med (PROF) is $7,037,000 on a trailing twelve months (TTM) basis.

What is the operating income of Profound Med (PROF)?

The operating income of Profound Med (PROF) is -$33,062,000.

What is the primary focus of Profound Med Corp?

Profound Med Corp specializes in developing and marketing incision-free, image-guided therapeutic systems for the ablation of diseased tissue, specifically focusing on prostate ablation.

How does the TULSA-PRO system work?

The TULSA-PRO system combines real-time MRI guidance with transurethral therapeutic ultrasound and closed-loop thermal feedback control, allowing for precise, patient-specific ablation of prostate tissue.

What architecture does Profound Med Corp use in its product design?

Their platform leverages existing MRI infrastructure, integrating advanced imaging with durable equipment and one-time use devices to seamlessly fit within current clinical settings.

How does Profound Med Corp differentiate itself in the competitive medical device market?

The company differentiates itself through its minimally invasive approach, emphasis on precision via closed-loop feedback, and its ability to deliver safe, efficient treatments tailored to individual patient anatomy.

What benefits does the system offer to patients?

The system provides short treatment times, low morbidity, and a tailored approach to prostate ablation, facilitating faster recovery compared to traditional invasive procedures.

How does the technology integrate with existing healthcare systems?

The product is designed to work alongside the healthcare system's existing MRI scanners, making it easier for clinics and hospitals to adopt the technology without extensive additional investments.

What roles do real-time imaging and thermal feedback play in the procedure?

Real-time MRI ensures that the treatment is precisely targeted and adjusted according to patient-specific conditions, while the closed-loop thermal feedback system maintains accurate temperature control during ablation.

What market segment does Profound Med Corp target?

Profound Med Corp targets the specialized medical device market focusing on non-invasive therapeutic systems, particularly those designed for the ablation of prostate tissue in patients with prostate cancer.